Carolin Barth joined Boston Consulting Group in May 2023. She is a core member of the Health Care practice, focusing on R&D and commercial strategy for biopharma companies. She brings to her role at BCG extensive E2E leadership experience in pharma and biotech across the entire value chain, with deep expertise in biologics and cell therapies for immunology and oncology.

Before coming to BCG, Carolin was CEO of a biotech company with a successful exit. Before that, she held various senior positions with Novartis Oncology/Novartis. Carolin is a physician with clinical experience in hemotology/oncology at University Hospital Tübingen. She serves as a trustee on the Board of the Institute of Cancer Research (ICR) in the UK.